

23.02.2023

08:25 - 09:50	Type: Educational session Title: Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023 Moderation: Isabelle Ray-Coquard, France; Susana Banerjee, United Kingdom	Auditorium 113
08:25 - 08:30	Welcome to the ESMO Gynaecological Cancers Congress 2023 <u>The Chairs</u> , Barcelona, Spain	
08:30 - 08:35	Introduction <u>Susana Banerjee</u> , London, United Kingdom	
08:35 - 08:50	Do we still need radical surgery in the PARP inhibitor era? <u>Giovanni Scambia</u> , Rome, Italy	
08:50 - 09:05	How to select the best first line maintenance treatment? Is molecular profiling the only criteria to choose? <u>Isabelle Ray-Coquard</u> , Lyon, France	
09:05 - 09:20	New treatment in the current ovarian cancer beyond ADCs <u>Nicoletta Colombo</u> , Milan, Italy	
09:20 - 09:35	PARP inhibitors: Mechanism of resistance and how to overcome <u>Iain Mcneish</u> , London, United Kingdom	
09:35 - 09:50	Q&A	
09:50 - 10:15	Type: Break Title: Coffee Break	Exhibition and Poster area

10:15 - 11:35	Type: Special Symposium Title: How to interpret overall survival data with PARP inhibitors Moderation: Robert Coleman, United States of America; Susana Banerjee, United Kingdom	Auditorium 113
10:15 - 10:30	Why are we having this Symposium? Recent regulatory actions by FDA/EMA regarding late-stage approval for PARPi in recurrent ovarian cancer <u>Robert Coleman</u> , The Woodlands, United States of America	
10:30 - 10:45	Is there clinical evidence to support the link between PARPi use and a negative impact on OS? <u>Jonathan Ledermann</u> , London, United Kingdom	
10:45 - 11:00	Is there a biological rationale to support decremental impact on overall survival? <u>Antonio Jose Gonzalez Martin</u> , Madrid, Spain	
11:00 - 11:35	Q&A	

11:45 - 12:45	Type: Proffered Paper session Title: Proffered Paper session Moderation: Bradley J. Monk, United States of America; Kathleen Moore, United States of America	Auditorium 113
11:45 - 11:53	320 - 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the Phase III PAOLA-1/ENGOT-ov25 trial <u>Domenica Lorusso</u> , Rome, Italy	
11:53 - 12:01	330 - PRIMA/ENGOT-OV26/GOG-3012 study: long-term conditional PFS <u>Antonio Jose Gonzalez Martin</u> , Madrid, Spain	
12:01 - 12:11	Invited Discussant of abstracts 320 and 330 <u>Kathleen Moore</u> , Oklahoma City, United States of America	
12:11 - 12:19	340 - ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss - results from the ENGOT/GYN1/NCRI ATARI trial <u>Susana Banerjee</u> , London, United Kingdom	
12:19 - 12:24	Invited Discussant of abstract 340 <u>Jean Emmanuel Kurtz</u> , Strasbourg, France	
12:24 - 12:32	350 - Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer Adjusted for Subsequent PARPi Use in Placebo Group: Results from an Ad Hoc Interim Analysis for the Phase 3 NORA Study <u>Xiaohua Wu</u> , Shanghai, China	
12:32 - 12:37	Invited Discussant of abstract 350 <u>Jonathan Ledermann</u> , London, United Kingdom	
12:37 - 12:45	Q&A and discussion	
12:45 - 13:45	Type: Break Title: Lunch Break	Exhibition and Poster area

13:00 - 13:45	Type: Young oncologists session Title: YO Mentorship session Moderation: Rodrigo Sanchez Bayona, Spain; Maria Kfoury, France	Foyer Bicolor
13:00 - 13:00	Table 1: How to succeed as a young investigator? <u>Isabelle Ray-Coquard</u> , Lyon, France	
13:00 - 13:00	Table 2: How to establish international collaborations? <u>Mansoor Raza Mirza</u> , Copenhagen, Denmark	
13:00 - 13:00	Table 3: How to plan translational research appended to clinical trial? <u>Charlie Gourley</u> , Edinburgh, United Kingdom	
13:45 - 14:45	Type: Industry satellite symposium Title: GSK - Shifting the treatment paradigm of OC/EC: Towards a new horizon Moderation: Ana Oaknin, Spain	Auditorium 113
13:45 - 13:50	Where are we now? Latest advances in treatment of gynecologic cancer <u>Ana Oaknin</u> , Barcelona, Spain	
13:50 - 14:10	Where are we going with OC? Evolving the management of 1L advanced ovarian cancer with PARPis <u>Iain Mcneish</u> , London, United Kingdom	
14:10 - 14:30	Where are we going with EC? Aiming to improve outcomes in primary advanced or recurrent endometrial cancer with PD-(L)1 inhibitors <u>Ainhoa Madariaga Urrutia</u> , Madrid, Spain	
14:30 - 14:45	Live Q&A and discussion <u>All Speakers</u> , Barcelona, Spain	

15:00 - 16:00	Type: Controversy session Title: How hot is HIPEC treatment in ovarian cancer? Moderation: Robert Coleman, United States of America	Auditorium 113
15:00 - 15:10	Introduction and first vote <u>Robert Coleman</u> , The Woodlands, United States of America	
15:10 - 15:30	The data absolutely support integration of HIPEC into primary ovarian cancer management (PRO) <u>Willemien Van Driel</u> , Amsterdam, Netherlands	
15:30 - 15:50	HIPEC is not "IT" (CON) <u>Leslie Randall</u> , Richmond, United States of America	
15:50 - 16:00	Second vote and conclusions <u>Robert Coleman</u> , The Woodlands, United States of America	
16:00 - 16:30	Type: Break Title: Coffee Break	Exhibition and Poster area
16:30 - 17:50	Type: Educational session Title: ADCs in gynaecological cancers Moderation: Bradley J. Monk, United States of America; Ilaria Colombo, Switzerland	Auditorium 113
16:30 - 16:35	Introduction <u>Bradley J. Monk</u> , Edgewater, United States of America	
16:35 - 16:50	Understanding the basics: Structure, key properties, mechanism of action, optimal diagnostic test to determine the target <u>Kathleen Moore</u> , Oklahoma City, United States of America	
16:50 - 17:05	The evolving ADC treatment landscape in ovarian cancer <u>Ilaria Colombo</u> , Bellinzona, Switzerland	
17:05 - 17:20	Role of ADCs in cervical cancer treatment in the era of immunotherapy <u>Bradley J. Monk</u> , Edgewater, United States of America	
17:20 - 17:35	The new challenge: ADC class effects, on/off-target adverse reactions and their interdisciplinary management <u>Toon Van Gorp</u> , Leuven, Belgium	
17:35 - 17:50	Q&A	

18:00 - 19:00	Type: ESMO Colloquium Title: ESMO Colloquium supported by Eisai Europe Ltd. - Management of patients with advanced endometrial cancer in the era of molecular oncology and immunotherapy Moderation: Vicky Makker, United States of America; Alexandra Leary, France	Auditorium 113
18:00 - 18:05	Introduction <u>Vicky Makker</u> , New York City, United States of America	
18:05 - 18:20	Emerging molecular profiling models for advanced endometrial cancer: Prognosticators and predictors of benefit from IO and targeted therapeutics <u>Tjalling Bosse</u> , Leiden, Netherlands	
18:20 - 18:35	The landscape of approved immune checkpoint inhibitors and TKI combinations in advanced endometrial cancer <u>Vicky Makker</u> , New York City, United States of America	
18:35 - 18:50	Research insights: New immunotherapy combinations in clinical development for gynecological malignancies <u>Alexandra Leary</u> , Villejuif, France	
18:50 - 18:55	Q&A	
18:55 - 19:00	Concluding remarks <u>Alexandra Leary</u> , Villejuif, France	
19:15 - 20:15	Type: Industry satellite symposium Title: AstraZeneca - Long-term survival for patients with newly-diagnosed advanced ovarian cancer (VIRTUAL ONLY) Moderation: Nicoletta Colombo, Italy	Auditorium 113
19:15 - 19:20	Welcome and introduction <u>Nicoletta Colombo</u> , Milan, Italy	
19:20 - 19:35	Evidence from first-line PARPi maintenance trials <u>Kathleen Moore</u> , Oklahoma City, United States of America	
19:35 - 19:50	Integrating the latest data into clinical practice <u>Jonathan Ledermann</u> , London, United Kingdom	
19:50 - 20:15	Panel discussion and Q&A <u>All Speakers</u> , Barcelona, Spain	

24.02.2023

08:30 - 09:50	Type: Educational session Title: Is cervical cancer still an orphan disease? Moderation: Kosei Hasegawa, Japan; Bradley J. Monk, United States of America	Auditorium 113
08:30 - 08:35	Introduction <u>Kosei Hasegawa</u> , Saitama, Japan	
08:35 - 08:50	Molecular profiling and pathology of cervical cancer patients: Are HPV negative tumors a different entity? <u>Camilla Krakstad</u> , Bergen, Norway	
08:50 - 09:05	Can we improve the prognosis of locally advanced cervical cancer? <u>Kosei Hasegawa</u> , Saitama, Japan	
09:05 - 09:20	Immunotherapy in cervical cancer: A paradigm shift <u>Domenica Lorusso</u> , Rome, Italy	
09:20 - 09:35	Innovative techniques in radiation oncology to increase cure and reduce toxicity <u>Dina Najjari Jamal</u> , Barcelona, Spain	
09:35 - 09:50	Q&A	
09:50 - 10:15	Type: Break Title: Coffee Break	Exhibition and Poster area

10:15 - 11:35	Type: Educational session Title: Endometrial cancer Moderation: Ana Oaknin, Spain; Domenica Lorusso, Italy	Auditorium 113
----------------------	--	-----------------------

10:15 - 10:20	Introduction <u>Domenica Lorusso</u> , Rome, Italy	
10:20 - 10:35	Revisiting the adjuvant therapy in endometrial cancer: ESMO Guidelines <u>Carien Creutzberg</u> , Leiden, Netherlands	
10:35 - 10:50	Is immunotherapy changing the face of recurrent/metastatic endometrial cancer? <u>Ana Oaknin</u> , Barcelona, Spain	
10:50 - 11:05	Are all dMMR/MSI-H endometrial cancer the same disease? <u>Xavier Matias-Guiu</u> , Hospitalet de Llobregat, Spain	
11:05 - 11:20	Beyond immunotherapy: What is the role of HER2, p53 and other molecular targets in the recurrent/metastatic endometrial cancer treatment landscape? <u>Mansoor Raza Mirza</u> , Copenhagen, Denmark	
11:20 - 11:35	Q&A	

11:45 - 12:15	Type: Keynote lecture Title: Keynote address Moderation: Domenica Lorusso, Italy	Auditorium 113
----------------------	--	-----------------------

11:45 - 11:50	Introduction to the Keynote lecture <u>Domenica Lorusso</u> , Rome, Italy	
11:50 - 12:15	Pandemomics: Challenging assumptions in gynecologic oncology <u>Michael Bookman</u> , San Francisco, United States of America	

12:15 - 13:00	Type: Meet the Expert session Title: Regeneron - VELOCISUITE: Leveraging Regeneron's technologies to produce an innovative therapeutic pipeline Moderation: Teresa Ramirez Montagut, United States of America	Room 122
12:15 - 12:45	VELOCISUITE: Leveraging Regeneron's technologies to produce an innovative therapeutic pipeline <u>Teresa Ramirez Montagut</u> , New York, United States of America	
12:45 - 13:00	Q&A and discussion <u>Teresa Ramirez Montagut</u> , New York, United States of America	
12:15 - 13:15	Type: Young oncologists session Title: YO Vesalius Talk: How to boost your career in academia? Moderation: Maria Kfoury, France; Rodrigo Sanchez Bayona, Spain	Room 120
12:15 - 12:15	Panellist <u>Kathleen Moore</u> , Oklahoma City, United States of America	
12:15 - 12:15	Panellist <u>Antonio Jose Gonzalez Martin</u> , Madrid, Spain	
12:15 - 12:15	Panellist <u>Jonathan Ledermann</u> , London, United Kingdom	
12:15 - 12:15	Panellist <u>Carien Creutzberg</u> , Leiden, Netherlands	
12:15 - 13:15	Type: Break Title: Lunch Break	Exhibition and Poster area

13:15 - 14:15	Type: Industry satellite symposium Title: Seagen - Driving towards the future of r/m cervical cancer treatment: Take a front seat for interactive expert perspectives on emerging and potential future therapy options Moderation: Ana Oaknin, Spain	Auditorium 113
13:15 - 13:20	Welcome and introduction <u>Ana Oaknin</u> , Barcelona, Spain	
13:20 - 13:45	What has changed and what's next in the 1L setting for r/m CC? <u>Ana Oaknin</u> , Barcelona, Spain	
13:45 - 14:10	What's new and how can we improve 2L management of r/m CC? <u>Isabelle Ray-Coquard</u> , Lyon, France	
14:10 - 14:15	Key messages and close <u>Ana Oaknin</u> , Barcelona, Spain	
14:30 - 15:50	Type: Multidisciplinary Tumour Board Title: Rare cancers Moderation: Domenica Lorusso, Italy; Isabelle Ray-Coquard, France	Auditorium 113
14:30 - 14:35	Introduction <u>Isabelle Ray-Coquard</u> , Lyon, France	
14:35 - 14:55	State-of-the-art management in carcinosarcoma: From the biology to treatment <u>Ignacio Romero</u> , Valencia, Spain	
14:55 - 15:15	Is immune therapy definitely required for all clear cell carcinoma? <u>Alexandra Leary</u> , Villejuif, France	
15:15 - 15:35	Which drugs could be relevant for LGSC: The present and future <u>Charlie Gourley</u> , Edinburgh, United Kingdom	
15:35 - 15:50	Q&A	
15:50 - 16:15	Type: Break Title: Coffee Break	Exhibition and Poster area
16:15 - 17:30	Type: Mini Oral session Title: Mini Oral session Moderation: Kosei Hasegawa, Japan	Auditorium 113
16:15 - 16:20	36MO - Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free	

survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial

Antonio Jose Gonzalez Martin, Madrid, Spain

- 16:20 - 16:25 **37MO - Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial**
Lingya Pan, Beijing, China
- 16:25 - 16:35 **Invited Discussant of abstracts 36MO and 37MO**
Rebecca Kristeleit, London, United Kingdom
- 16:35 - 16:40 **22MO - Homologous Recombination Gene Mutations in Uterine Serous Cancer: A Phenotype of the Hereditary Breast and Ovarian Cancer Syndrome?**
Muhammad Danyal Ahsan, New York, United States of America
- 16:40 - 16:45 **38MO - Validation study of the shallowHRDv2 assay for Homologous Recombination Deficiency (HRD) detection in high-grade ovarian carcinomas (HGOc) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial**
Céline Callens, Paris, France
- 16:45 - 16:50 **39MO - Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer**
Romain Boidot, Dijon, France
- 16:50 - 16:55 **1MO - Identification of RAD51 foci in cancer-associated circulating cells and their association with treatment outcomes, in patients with high-grade serous ovarian cancer (HGSOC)**
Marcia Hall, Northwood, United Kingdom
- 16:55 - 17:10 **Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO**
Iain Mcneish, London, United Kingdom
- 17:10 - 17:15 **40MO - Targetable Gene Mutations in Mucinous Ovarian Cancer**
Sarah Levi, New York, United States of America
- 17:15 - 17:20 **74MO - Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era: reassessing the Stage IVb designation**
Sean Koerner, Pittsburgh, United States of America
- 17:20 - 17:30 **Invited Discussant of abstracts 40MO and 74MO**
Robert Coleman, The Woodlands, United States of America